(RTTNews) - Abbott (ABT) said data from an investigator-sponsored European trial found managing indicated heart failure patients with CardioMEMS HF System resulted in a significant improvement in ...

CardioMEMS ran into a regulatory roadblock last week, when an FDA advisory panel recommended that the agency not approve the company's Champion HF Monitoring System. The device is said to be the first ...

Abbott Laboratories, Inc. ABT presented new data from an investigator-sponsored European study — MONITOR-HF. The study revealed that Abbott's CardioMEMS HF System led to a significant improvement in ...

In the first randomized clinical trial of remote pulmonary artery pressure–guided monitoring and management of chronic heart failure (HF) in Europe, the intervention "substantially" improved quality ...

December 8, 2011 (Gaithersburg, Maryland) — An FDA advisory panel collectively decided a tiny pulmonary-artery (PA) pressure monitor for patients with heart failure (HF) isn't ready for prime time.